Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Hydrochlorothiazide · Hydrodiuril, NSC-53477

Small molecule · developed by Merck

Approved FDA, Feb 1959
1 Registered trials

What is Hydrochlorothiazide?

Hydrochlorothiazide is a short-acting thiazide diuretic that is primarily excreted by the kidneys. It is widely used to treat hypertension and edema. Its metabolite appears to preferentially bind to and accumulate in red blood cells.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Hydrodiuril, NSC-53477, SU-5879
Drug type
Small molecule
Therapy area
Cardiovascular
Developer
Merck
In trials of
LGND
FDA status
Approved as Hydrodiuril (February 24, 1959), NDA011835
UNII
0J48LPH2TH

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05685277 Phase 1 Bioequivalence Completed LGND

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Bioequivalence

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.